2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2339

Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Abstract Number: 2340

Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Abstract Number: 2341

Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Abstract Number: 2342

Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Abstract Number: 2343

Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Abstract Number: 2344

Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 2345

Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
Abstract Number: 2346

Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Abstract Number: 2347

Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center
Abstract Number: 2348

KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD
Abstract Number: 2349

Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Abstract Number: 2350

Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Abstract Number: 2351

Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Abstract Number: 2352

Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
Abstract Number: 2353

ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].